ASCO GI (Virtual)Phase 2/3 Study of SM-88 in Patients With Metastatic Pancreatic CancerAbstract 321873
AACR (Virtual)In Vivo Mouse Model Data Demonstrating Reduction in Tumor Cell Proliferation Following Intra-tumoral Administration of TYME-18Poster 2764 🔊Poster Audio Commentary
AACR (Virtual)In Vitro and In Vivo Anticancer Effects of D/L-alpha-metyrosine (SM-88), A Novel Metabolism-Based TherapyPoster 5998 🔊Poster Audio Commentary
ASCO GI (San Francisco, CA)An Assessment of the Total Cost of Pancreatic Cancer Using Real-World EvidenceAbstract 773
ASCO GI (San Francisco, CA)TYME-88-Panc Part 2: A Randomized Phase 2/3 of SM-88 with MPS as Third-Line in Metastatic PDACAbstract TPS789
ESMO Congress (Barcelona, Spain)Phase II Trial of SM-88 in Non-Metastatic Biochemical Recurrent Prostate Cancer Abstract: 3611
ESMO Congress (Barcelona, Spain)Phase II Monotherapy Efficacy of Cancer Metabolism Targeting SM-88 in Heavily Pre-Treated PDAC PatientsAbstract: 4283
AACR Special Conference (Boston, MA) CTC-based Efficacy of SM-88 Correlates with Overall Survival in Advanced Pancreatic CancerAbstract: 54116822
AACR Special Conference (Boston, MA) Therapeutic Potential of Targeting Amino Acid Metabolism in Pancreatic CancerAbstract: 78677080
ESMO World GI (Barcelona, Spain)SM-88 Therapy In High-risk Poor Prognosis Pancreatic CancerAbstract: 160
ASCO GU (San Francisco, CA)Evaluating Non-hormonal Therapy in a Phase II Trial of SM-88 for Rising PSA Prostate CancerAbstract: 83
ASCO GU (San Francisco, CA)Typical Hormone Deprivation Side Effects Compared to SM-88 Therapy for Rising PSAAbstract: 79
ASCO GI (San Francisco, CA)Phase II Trial of SM-88 in Patients with Metastatic Pancreatic Cancer: Preliminary Results of the 1st StageAbstract: 200 (rev.1/18/19 10:43 AM ET)
ASCO GI (San Francisco, CA)Phase II Pharmacokinetics of Oral SM-88 in Heavily Pre-Treated Advanced Pancreatic Ductal Adenocarcinoma (PC)Abstract: 277
ASCO GI (San Francisco, CA)Feasibility of SM-88 in Pancreatic Cancer After Multiple Prior Lines and ECOG ≤ 2Abstract: 310
ASCO GI (San Francisco, CA)Designing Clinical Trials in 3rd Line or Greater Pancreatic CancerAbstract: 226
ASCO General Meeting Poster TPS4156 SM-88 in Advanced Cancers of the Pancreas
ASCO General Abstract e13100 SM-88 Efficacy and Safety in Metastatic Breast Cancers
ASCO General Abstract e24072 Prospective Comparison of Invasive Circulating Tumor Cells (iCTCs) vs PSA and mPFS in Prostate Cancer (PC) Treated with SM-88
ASCO General Abstract e14535 SM-88 Efficacy Across Multiple High-Risk Factors
ASCO General Abstract e14528 Comparison of SUV and RECIST Responses in Cancers Treated with SM-88
ASCO GU Poster 2018 Phase II Trial of SM-88 in Non-Metastatic Biochemical Recurrent Prostate Cancer
ASCO GI Poster 2018 SM-88 Therapy in Patients with Advanced or Metastatic Pancreatic Cancer
ASCO Poster 2017 – A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of TYME-88 (SM-88) in Patients with Prostate Cancer
A phase Ib/II, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer. Abstract: TPS2615
SMK/SM88 toxicity, efficacy, and patient-reported outcomes in metastatic pancreas cancer. Abstract: e14060
Phase Ib pharmacokinetics of non-hormonal SM88 in patients with non-metastatic recurrent prostate cancer. Abstract: E14061
SM88/SMK non-hormonal therapy in recurrent or untreated prostate cancer. Abstract: E16540
SM88 in non-metastatic rising PSA-recurrent prostate cancer. Abstract: E16567
ESMO 2017 SM-88 Poster. September 2017
ESMO 2016 Preclinical Data Poster. October 2016